Table 1.
Demographic and clinical data for the study population of patients receiving linezolid
| Number | Median | Observation interval | ||
|---|---|---|---|---|
| Lower 2.5% | Upper 97.5% | |||
| Total patients | 81 | |||
| Male | 51 | |||
| Female | 30 | |||
| Administration route | ||||
| i.v | 54 | |||
| p.o. | 13 | |||
| Both | 14 | |||
| Observed total concentration (mg l–1) | 493 | 11.2 | 2.0 | 50.7 |
| Observed unbound concentration (mg l–1) | 380 | 1.9 | 0.3 | 8.8 |
| Protein binding ratio (%) | 17.0 | 7.6 | 33.3 | |
| Observed platelet count (×103 μl–1) | 575 | 160 | 22 | 463 |
| Observed haemoglobin level (g d l–1) | 595 | 8.6 | 6.1 | 15.0 |
| Age (years) | 69 | 8 | 85 | |
| Total body weight (kg) | 53.2 | 21.0 | 99.5 | |
| Infections diagnosed | ||||
| Sepsis | 26 | |||
| Wound, skin and soft tissue | 25 | |||
| Pneumonia | 14 | |||
| Abscess | 8 | |||
| Osteomyelitis | 6 | |||
| Undetermined | 2 | |||
| AST(IU l–1) | 22 | 10 | 163 | |
| ALT (IU l–1) | 20 | 4 | 190 | |
| Serum creatinine (mg dl–1) | 0.80 | 0.20 | 7.49 | |
| CLcr (ml min–1) | 59.6 | 5.6 | 188.4 | |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CLcr, creatinine clearance; i.v., intravenously; PI, percentile interval; p.o., orally